

VEITH FORUM Connecting The Vascular Community EVID AM

When Is Urgent (Within 48 Hours) CEA Or CAS Fairly Indicated After A Stroke: How Does Use Of tPA Influence Indications And Neurologic Outcomes In This Setting?

Hernan Bazan, MD DFSVS FACS

John Ochsner Endowed Professor of Surgery and Cardiovascular Innovation
Program Director, Vascular Fellowship
Section of Vascular/Endovascular Surgery, Department of Surgery

November 22, 2024

OchsnerHealth

VEITH FORUM Connecting The Vascular Community EVID AM

When Is Urgent (Within 48 Hours) CEA Or CAS Fairly Indicated After A Stroke: How Does Use Of tPA Influence Indications And Neurologic Outcomes In This Setting?

No Relevant Financial Disclosures

OchsnerHealth

Crescendo TIAs & Stroke-in-Evolution (SIE) Fluctuating Neurologic Symptoms

Vulnerable (Unstable) Plaque

Fibrous cap thinning → Plaque rupture mechanism for a recurrent stroke following a TIA or stroke

% Risk	Days	Fluctuating Symptoms
2 - 8	2	
4 - 17	3	
4 - 22	7	
7.5 - 25	14	

Risk of ipsilateral ischemic stroke recurrence after initial carotid-related TIA or stroke

Bazan H et al. J Vasc Med Biol. 2013;25(1):1-6. doi:10.1177/1043986212470000. Epub 2012 Aug 22. Available from: https://pubmed.ncbi.nlm.nih.gov/22888888/

Emergent (Within 48 Hours) CEA Or CAS for Crescendo TIAs and SIE

How Thrombolysis & NIHSS Influence Neurologic Outcomes

Vulnerable Carotid Plaque → Crescendo TIAs Stroke-in-evolution → +/- Thrombolysis → +/- Mechanical Endovascular Reperfusion (MER) → Stroke Severity (NIHSS) & Carotid Intervention Timing → Emergent CEA or CAS?

Neurologic Outcomes modified Rankin Scale (mRS)

Functional Independence mRS = 0-2

Dependence mRS = 3-5

NIHSS → Objective Criteria to Assess Stroke Severity

mRS → Outcome Measure for Post-Stroke Functional Dependence

Ischemic brain lesion on imaging has strong correlation with NIHSS

Stroke severity	NIHSS	Brain Density
< 4	minor	Impacted
5 - 15	moderate	
16 - 20	moderate-severe	
21 - 24	severe	

Neurologic Outcomes	modified Rankin Scale	mRS
0 asymptomatic		
1 no significant disability (facial droop)		
2 slight disability (grip problems)		
3 moderate disability (walks w/out assistance)		
4 moderate-severe disability (needs assistance to walk)		
5 Severe disability (bedridden)		
6 Death		

Functional dependence

Functional dependence (on caregiver)

U.S. 'Stroke Belt'

Regionalization Stroke Care with Increasing Comprehensive Stroke Centers

CDC, U.S. Stroke Death Rates, 2018 - 2020

Ochsner Tele-Stroke Network

Urgent CEA/CAS

Crescendo TIAs & Stroke-in-Evolution

These are Rare cases

- Previously functional
- No ICH
- Core infarct (small) and penumbra (large)

Consider going for it

Emergent CAS (MAMA (Proximal Protection) + Aspiration) | Emergent CEA + Aspiration | Pre- | Post-

Presenting Stroke Severity & Outcomes in all Acute Stroke Interventions

For acute carotid interventions

Presenting NIHSS Score influences Odds of Functional Independence (mRS ≤ 2)

Functional independence (mRS ≤ 2)
NIHSS 0-10 vs >10: **3.11 (1.33-7.33)**

- The odds of functional independence (mRS ≤ 2) following uCEA/uCAS are **3x-higher** if the presenting NIHSS ≤ 10 vs. NIHSS > 10
- Those presenting with an NIHSS ≤ 10 do significantly better with urgent carotid interventions (**3x better**) compared to NIHSS > 10

Thrombolysis may Pose Increased Risk

Stroke & Death; ICH / bleeding

SYSTEMATIC REVIEW
A Systematic Review and Meta-analysis of Peri-Procedural Outcomes in Patients Undergoing Carotid Interventions Following Thrombolysis

Study	Thrombolysis Events	No thrombolysis Events	Total	OR for peri-procedural stroke and death (95% CI)
CEA				
Subtotal ¹	7	351	358	1.52 (0.41-5.62)
JAMA 2021 ²¹	22	1895	1917	
CMAJ 2021 ²²	1	132	133	
Stroke 2020 ²³	3	27	30	
Stroke 2015 ²⁴	2	2	4	
Stroke 2018 ²⁵	4	11	15	
Stroke 2019 ²⁶	4	11	15	
Stroke 2020 ²⁷	1	1	2	
Stroke 2020 ²⁸	1	1	2	
Stroke 2020 ²⁹	1	1	2	
Stroke 2020 ³⁰	1	1	2	
Stroke 2020 ³¹	1	1	2	
Stroke 2020 ³²	1	1	2	
Stroke 2020 ³³	1	1	2	
Stroke 2020 ³⁴	1	1	2	
Stroke 2020 ³⁵	1	1	2	
Stroke 2020 ³⁶	1	1	2	
Stroke 2020 ³⁷	1	1	2	
Stroke 2020 ³⁸	1	1	2	
Stroke 2020 ³⁹	1	1	2	
Stroke 2020 ⁴⁰	1	1	2	
Stroke 2020 ⁴¹	1	1	2	
Stroke 2020 ⁴²	1	1	2	
Stroke 2020 ⁴³	1	1	2	
Stroke 2020 ⁴⁴	1	1	2	
Stroke 2020 ⁴⁵	1	1	2	
Stroke 2020 ⁴⁶	1	1	2	
Stroke 2020 ⁴⁷	1	1	2	
Stroke 2020 ⁴⁸	1	1	2	
Stroke 2020 ⁴⁹	1	1	2	
Stroke 2020 ⁵⁰	1	1	2	
Stroke 2020 ⁵¹	1	1	2	
Stroke 2020 ⁵²	1	1	2	
Stroke 2020 ⁵³	1	1	2	
Stroke 2020 ⁵⁴	1	1	2	
Stroke 2020 ⁵⁵	1	1	2	
Stroke 2020 ⁵⁶	1	1	2	
Stroke 2020 ⁵⁷	1	1	2	
Stroke 2020 ⁵⁸	1	1	2	
Stroke 2020 ⁵⁹	1	1	2	
Stroke 2020 ⁶⁰	1	1	2	
Stroke 2020 ⁶¹	1	1	2	
Stroke 2020 ⁶²	1	1	2	
Stroke 2020 ⁶³	1	1	2	
Stroke 2020 ⁶⁴	1	1	2	
Stroke 2020 ⁶⁵	1	1	2	
Stroke 2020 ⁶⁶	1	1	2	
Stroke 2020 ⁶⁷	1	1	2	
Stroke 2020 ⁶⁸	1	1	2	
Stroke 2020 ⁶⁹	1	1	2	
Stroke 2020 ⁷⁰	1	1	2	
Stroke 2020 ⁷¹	1	1	2	
Stroke 2020 ⁷²	1	1	2	
Stroke 2020 ⁷³	1	1	2	
Stroke 2020 ⁷⁴	1	1	2	
Stroke 2020 ⁷⁵	1	1	2	
Stroke 2020 ⁷⁶	1	1	2	
Stroke 2020 ⁷⁷	1	1	2	
Stroke 2020 ⁷⁸	1	1	2	
Stroke 2020 ⁷⁹	1	1	2	
Stroke 2020 ⁸⁰	1	1	2	
Stroke 2020 ⁸¹	1	1	2	
Stroke 2020 ⁸²	1	1	2	
Stroke 2020 ⁸³	1	1	2	
Stroke 2020 ⁸⁴	1	1	2	
Stroke 2020 ⁸⁵	1	1	2	
Stroke 2020 ⁸⁶	1	1	2	
Stroke 2020 ⁸⁷	1	1	2	
Stroke 2020 ⁸⁸	1	1	2	
Stroke 2020 ⁸⁹	1	1	2	
Stroke 2020 ⁹⁰	1	1	2	
Stroke 2020 ⁹¹	1	1	2	
Stroke 2020 ⁹²	1	1	2	
Stroke 2020 ⁹³	1	1	2	
Stroke 2020 ⁹⁴	1	1	2	
Stroke 2020 ⁹⁵	1	1	2	
Stroke 2020 ⁹⁶	1	1	2	
Stroke 2020 ⁹⁷	1	1	2	
Stroke 2020 ⁹⁸	1	1	2	
Stroke 2020 ⁹⁹	1	1	2	
Stroke 2020 ¹⁰⁰	1	1	2	

Thrombolysis Patients Presenting with Higher Stroke Severity

Higher mortality

Patients receiving thrombolysis are presenting with **more severe stroke (higher NIHSS scores)**, requiring more aggressive intervention

- Stroke Severity (NIHSS): **7.6 vs. 3.8** (P < 0.001)

Guidelines Urge Caution Amid Limited Evidence


CEA within 24h for cTIAs & SIE

Guidelines	Recommendation	Strength of Recommendation	Evidence Quality
ESVS 2023	Stroke-in-evolution or crescendo TIAs < 24h	IIA, Moderate	Low
SYS 2022	Repetitive episodes (cTIAs) unresponsive to antiplatelet therapy should be considered for urgent CEA.		
SYS 2022	SIE/cTIAs within 24 hours		
SYS 2022	After IV thrombolysis, early CEA (≤14 days) is viable if rapid recovery (mRS 0-3), infarct <30% MCA, recanalized MCA, no ICH and minimal brain edema.		

Conclusions: CEA or CAS within 48 hours

Crescendo TIAs & Stroke-in-Evolution: Rare cases – Fluctuating Symptoms < 24 hrs

- Consider CEA / CAS:
 - No ICH
 - Previously highly functional
 - Small core infarct & large ischemic penumbra
- Stroke severity (NIHSS) is strongest predictor of neurologic outcomes (mRS)
- Thrombolysis increases bleeding risk, but it's associated with better neurologic outcomes
- Don't deny a patient CEA or CAS simply because they received thrombolysis, especially in cTIAs/SIE



When Is Urgent (Within 48 Hours) CEA Or CAS Fairly Indicated After A Stroke: How Does Use Of tPA Influence Indications And Neurologic Outcomes In This Setting?

Thank you

